In the issue:
Vitamin D status and haematological malignancy risk
Leukaemia selection
Maintenance lenalidomide in previously treated CLL
Second TKI discontinuation attempt in CML
CLL treated with CD19-specific CAR-T-cells after ibrutinib failure
Lymphoma selection
Rituximab after autologous SCT in mantle-cell lymphoma
First-line obinutuzumab in follicular lymphoma
Development of the MALT-IPI
Consistently poor outcomes in refractory DLBCL
Haplo-identical vs. matched sibling/unrelated donor transplantation for Hodgkin’s
Baseline metabolic tumour volume prognostic in relapsed/ refractory Hodgkin’s
Please login below to download this issue (PDF)